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Analysis of predicted loss-of-function variants in
UK Biobank identiﬁes variants protective for
disease
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Less than 3% of protein-coding genetic variants are predicted to result in loss of protein
function through the introduction of a stop codon, frameshift, or the disruption of an essential
splice site; however, such predicted loss-of-function (pLOF) variants provide insight into
effector transcript and direction of biological effect. In >400,000 UK Biobank participants,
we conduct association analyses of 3759 pLOF variants with six metabolic traits, six
cardiometabolic diseases, and twelve additional diseases. We identiﬁed 18 new
low-frequency or rare (allele frequency < 5%) pLOF variant-phenotype associations. pLOF
variants in the gene GPR151 protect against obesity and type 2 diabetes, in the gene IL33
against asthma and allergic disease, and in the gene IFIH1 against hypothyroidism. In the
gene PDE3B, pLOF variants associate with elevated height, improved body fat distribution
and protection from coronary artery disease. Our ﬁndings prioritize genes for which
pharmacologic mimics of pLOF variants may lower risk for disease.
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A focused investigation of predicted loss-of-function(pLOF) variants provides several advantages whencompared with analysis of other types of variants. First,
analysis of pLOF variants may allow for the direct identiﬁcation
of a gene rather than a locus containing many candidate genes1.
Second, pLOF variants provide directionality of effect, unlike
non-coding regulatory variants which may increase or decrease
expression of a given gene. Third, identiﬁcation of pLOF variants
which protect against disease may aid with prioritization of
therapeutic target genes (e.g., the recent development of inhibi-
tors of PCSK9 or ANGPTL3 which mimic human pLOF
mutations protective against cardiovascular disease)2–6.
Here, we analyse pLOF variants in UK Biobank and other
datasets to identify genes for which pharmacologic inhibition may
protect against disease. We identify associations of pLOF variants
with cardiometabolic and immune disease, prioritizing the
genes GPR151, IL33, GSDMB, IFIH1, and PDE3B as potential
therapeutic targets.
Results
Analysis of loss-of-function variants. In 405,569 individuals in
UK Biobank (335,660 individuals of European ancestry and
69,909 individuals of Non-European ancestry, Supplementary
Table 1), we analyzed the association of 3759 pLOF variants with
six metabolic traits [body mass index (BMI), waist-to-hip ratio
adjusted for body mass index (WHRadjBMI), height, systolic
blood pressure (SBP), diastolic blood pressure (DBP), forced
expiratory volume to forced vital capacity ratio (FEV1/FVC)], six
cardiometabolic diseases (coronary artery disease, type 2 diabetes,
atrial ﬁbrillation, stroke, heart failure, venous thromboembolism)
and twelve diseases with more than 5000 cases (allergic rhinitis,
asthma, anxiety, breast cancer, cataract, cholelithiasis, depression,
hypothyroidism, gastric reﬂux, osteoporosis, osteoarthritis, and
psoriasis). The Variant Effect Predictor and associated LOFTEE
plugin7,8 algorithms were used to annotate variants which were
pLOF (1) nonsense mutations that resulted in early termination
of a protein; (2) frameshift mutations due to insertions or
deletions of DNA; or (3) splice-site mutations which result in an
incorrectly spliced protein. For coronary artery disease, we pooled
UK Biobank estimates with estimates from the CARDIoGRAM
Exome consortium9. For height, we pooled UK Biobank estimates
with estimates from the GIANT Exome Consortium10. Variants
with a P < 5.5 × 10−7 [0.05/(24 outcomes × 3759 variants) in the
combined analysis were considered signiﬁcant. Quantile–quantile
analysis was used to examine for the presence of population
stratiﬁcation. No evidence of inﬂation was observed (inﬂation
factors <1.1; Supplementary Fig. 1).
We identiﬁed 18 new low-frequency or rare (<5%) pLOF
variants associated with traits and diseases in UK Biobank
(Table 1 and Supplementary Table 2). We also discovered 26 new
common frequency (≥5%) pLOF variants associated with UK
Biobank phenotypes (Supplementary Table 3). Variants identiﬁed
within the same locus in prior genome-wide association studies
(+500 Kb; 1 Mb total) for the same phenotype are provided
(Supplementary Tables 4 and 5).
A locus-wide conditional analysis (±500 kb of the pLOF
variant) was performed to determine the extent to which the
identiﬁed pLOF variant signal was independent of other genetic
variation at the locus. Independence of pLOF variants may
provide increased conﬁdence for a causal association. Indepen-
dent variants at the loci of rare and low frequency pLOFs are
reported in Supplementary Data 1 and independent variants at
the loci of common frequency pLOFs are reported in
Supplementary Data 2. Of the 16 low frequency pLOF variants
outside of the MHC locus, 14 were identiﬁed as independent
variants in the locus-wide conditional analysis. These include the
IL33 variant rs146597587, the GPR151 variant rs114285050, the
IFIH1 variant rs35337543, and the PDE3B variant rs15009066
which are further analyzed in the text of this manuscript. Below,
we highlight several of these associations.
GPR151, obesity, and type 2 diabetes. In GPR151 (encoding
G-protein coupled receptor 151), the p.Arg95Ter variant
(rs114285050, allele frequency 0.8% in European ancestry) was
associated with reduced BMI (beta −0.07 standard deviations,
−0.36 kg/m2, P= 4.9 × 10−8). We replicated this association in
an independent cohort, the Myocardial Infarction Genetics
Consortium (MIGen), where p.Arg95Ter carriers had reduced
Table 1 Predicted loss-of-function variants with minor allele frequency <5% which are signiﬁcantly associated with traits or
diseases in UK Biobank
Outcome Gene pLOF variant Location EA RA AA change Freq (%) Beta SE P-value Novel? MHC locus?
Asthma FLG rs61816761 1:152285861 A G p.Arg501Ter 1.51 0.21 0.03 1.51 × 10−15 Yes No
Asthma HLA-DQB1 rs28688207 6:32628660 C T Splice Acceptor c.773−1A > G 3.14 −0.17 0.02 3.11 × 10−15 Yes Yes
Asthma IL33 rs146597587 9:6255967 C G Splice Acceptor c.487−1G > C 0.44 −0.54 0.06 7.79 × 10−17 No15 No
BMI GPR151 rs114285050 5:145895394 A G p.Arg95Ter 0.78 −0.07 0.01 4.89 × 10−8 Yes No
BMI PKHD1L1 rs533623778 8:110523131 T C p.Arg769Ter 1.0 × 10−4 5.30 0.99 9.45 × 10−8 Yes No
DBP ENPEP rs33966350 4:111431444 A G p.Trp413Ter 1.19 0.06 0.01 8.12 × 10−10 No39 No
DBP BTN3A2 rs58367598 6:26370833 G T Splice Donor c.715+ 2T > G 3.75 0.03 0.01 2.03 × 10−8 Yes Yes
DBP TMC3 rs150843673 15:81624929 T G p.Ser1045Ter 2.14 0.05 0.01 8.16 × 10−9 Yes No
Height PDE11A rs76308115 2:178879181 A G p.Arg57Ter 0.52 0.07 0.01 6.20 × 10−11 Yes No
Height CLHC1 rs114931154 2:55407644 T A Splice Donor c.1384+ 2T > A 1.26 −0.05 0.01 1.54 × 10−11 Yes No
Height CCDC66 rs150364083 3:56628033 T C p.Arg427Ter 0.58 0.05 0.01 2.09 × 10−7 Yes No
Height DAP rs201354802 5:10761153 A C p.Glu10Ter 0.24 0.13 0.02 1.68 × 10−8 Yes No
Height TRIM40 rs115651142 6:30115320 T G Splice Donor c.602+ 1G > T 0.63 −0.08 0.01 1.16 × 10−9 Yes Yes
Height MICA rs181430930 6:31378575 A G Splice Donor c.286+ 1G > A 0.26 −0.12 0.02 7.87 × 10−8 Yes Yes
Height PDE3B rs150090666 11:14865399 T C p.Arg783Ter 0.06 0.24 0.04 9.32 × 10−9 Yes No
Height APOLD1 rs202116412 12:12879031 A G Splice Donor c.96+ 1G > A 0.03 0.12 0.02 3.06 × 10−8 Yes No
Hypothyroidism IFIH1 rs35337543 2:163136505 G C Splice Donor c.1641+ 1G > C 1.45 −0.27 0.04 2.95 × 10−9 Yes No
Psoriasis ZKSCAN3 rs73387810 6:28318166 A G Splice Donor c.−63+ 1G > A 0.86 0.55 0.08 4.18 × 10−11 Yes Yes
Psoriasis EGFL8 rs141826798 6:32134395 G C p.Arg74Ter 0.53 0.90 0.08 2.19 × 10−26 Yes Yes
SBP ENPEP rs33966350 4:111431444 A G p.Trp413Ter 1.19 0.06 0.01 3.46 × 10−9 No39 No
SBP GEM rs138582164 8:95264265 A G p.Arg199Ter 0.04 0.30 0.06 1.93 × 10−7 No40 No
WHRadjBMI PYGM rs116987552 11:64527223 A G p.Arg50Ter 0.39 0.09 0.02 1.32 × 10−7 Yes No
Beta in terms of standard deviations and reported for the effect allele
pLOF predicted loss-of-function, EA effect allele, RA reference allele, AA Change amino acid change, Freq(%) Frequency(%); BMI body mass index, DBP diastolic blood pressure, SBP systolic blood
pressure, WHRadjBMI waist-to-hip ratio adjusted for body mass index
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BMI (beta −0.14, P= 0.04; pooled beta −0.07, P= 9.8 × 10−9;
Fig. 1). UK Biobank participants who carry one copy of
p.Arg95Ter were at 12% lower odds of clinical obesity
(BMI > 30 kg/m2). As obesity is a causal risk factor for type 2
diabetes and coronary artery disease, we examined whether
p.Arg95Ter may provide protection against both diseases.
p.Arg95Ter was associated with 14% lower odds of type 2 diabetes
(OR 0.86; P= 0.006) and 9% lower odds of coronary artery
disease (OR 0.91; P= 0.01; Fig. 1). Although GPR151 encodes a
G-protein coupled receptor of unknown function whose
expression is limited to the central nervous system, recent studies
tracing the lineage of neurons expressing GRP151 have localized
connections to hypothalamic neurons, a region of the brain
important in the control of appetite11.
IL33, GSDMB, and asthma. We identiﬁed several pLOF variants
that associated with lower risk of asthma (Table 1). At GSDMB
encoding gasdermin B, splice acceptor variant c.662-2A > G
(rs11078928, allele frequency 46% in European ancestry) pro-
tected against asthma (OR 0.90 CI 0.89, 0.91, P= 6.7 × 10−50;
Supplementary Table 3). This variant is in tight linkage dis-
equilibrium (r2= 0.99) with a previously identiﬁed non-coding
variant in the GSDMB locus (rs2305480) associated with lower
risk of asthma (P= 9.6 × 10−8)12. GSDMB c.662-2A > G is
associated with lower expression of GSDMB transcripts13.
Furthermore, overexpression of GSDMB causes airway remodel-
ing and asthma symptoms in a mouse model14, suggesting that
loss of GSDMB function may protect against asthma.
At the IL33 gene, a splice acceptor site variant c.487-1G > C
(rs146597587, allele frequency 0.004 in European ancestry) was
observed to protect against asthma (OR 0.58 CI 0.51, 0.66,
P= 7.8 × 10−17). This variant was recently identiﬁed as associated
with lower blood eosinophil concentration at genome-wide
signiﬁcance and with lower risk of asthma at more modest levels
of signiﬁcance (P= 1.8 × 10−4)15. To further replicate the
association of IL33 c.487-1G > C with asthma, we examined the
association of IL33 c.487-1G > C with asthma in individuals from
three additional studies (Partners Biobank, the Vanderbilt
eMERGE network, and the Women’s Genome Health Study).
IL33 c.487-1G > C was associated with a protective effect of
asthma in each data set. Overall, IL33 c.487-1G > C was
associated with 43% lower odds of asthma (OR 0.57 CI 0.51,
0.65, P= 9.6 × 10−19, Fig. 2), suggesting that IL33 inhibition may
be a useful approach for treatment of asthma. Of note, an
inhibitor of IL33 is currently under development for treatment of
asthma16.
Asthma is often associated with other allergic phenotypes—
atopic dermatitis, food allergy, and allergic rhinitis17. We
therefore examined whether asthma-associated pLOF variants
in GSDMB and IL33 associate with a lower risk of other
atopic disorders in UK Biobank. Both pLOF variants also
protected against allergic rhinitis (Fig. 3). In contrast, nominal
associations with atopic dermatitis and food allergy were not
observed, although point estimates for food allergy were similar
to asthma.
IFIH1 and autoimmune disorders. A splice donor variant in
IFIH1 (interferon induced with helicase C domain 1), c.1641+
1G > C (rs35337543, allele frequency 1.5% in European ancestry),
is associated with a reduced risk of hypothyroidism in UK
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Fig. 1 Association of a loss-of-function variant (p.Arg95Ter) in GPR151 with a body mass index, b type 2 diabetes, and c coronary artery disease. Estimates
were derived in UK Biobank using logistic regression, adjusted for age, sex, ten principal components of ancestry, and array type
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Biobank participants (OR 0.77 CI 0.70, 0.85; P= 5 × 10−9;
Table 1). A gene-based test combining four additional
pLOF variants in IFIH1 (rs35732034, rs201026962, rs35744605,
rs148590996) similarly demonstrated protection against
hypothyroidism in UK Biobank (OR 0.79 CI 0.72, 0.86; P= 4.4 ×
10−8). Carriers of pLOF variants in IFIH1 were also protected
against hyperthyroidism (OR 0.84 CI 0.73, 0.96; P= 0.01; Fig. 4).
Common variants in the IFIH1 locus have previously been
associated with psoriasis18 and vitiligo19, while rare pLOF
variants in IFIH1 have been associated with a reduced risk of
type 1 diabetes20. We therefore examined whether carriers of
pLOF variants in IFIH1 in UK Biobank were protected against
these diseases. Carriers of pLOF variants in IFIH1 were protected
against type 1 diabetes, psoriasis, and vitiligo in UK Biobank
(Fig. 4). These results suggest that IF1H1 pLOF variants alter risk
for a range of autoimmune diseases.
In addition, an exploratory analysis demonstrated a nominally
lower risk of coronary artery disease among IFIH1 pLOF carriers.
Pooling UK Biobank and MIGen, IFIH1 pLOF carriers were
protected against coronary artery disease (OR 0.92 CI 0.87, 0.98;
P= 0.009). To examine whether this may be a chance ﬁnding, we
examined whether the common IFIH1 missense variant
rs1990760, previously identiﬁed as associated with autoimmune
disorders, also associated with risk of coronary artery disease. The
T allele of rs1990760 (frequency 41%) associated with a reduced
risk of hypothyroidism (OR 0.92 CI 0.90, 0.94; P= 9.3 × 10−17) in
UK Biobank. Pooling UK Biobank and CARDIOGRAM Exome,
the T allele of rs1990760 also associated with a lower risk of
coronary artery disease (OR 0.97 CI 0.96, 0.99; P= 2.5 × 10−5),
providing complementary evidence that IFIH1 may inﬂuence
coronary artery disease risk.
PDE3B and body fat distribution. At PDE3B encoding the
gene phosphodiesterase 3B, p.Arg783Ter (rs150090666, allele
frequency 0.0006 in European ancestry) associated with elevated
height (beta 0.24, P= 9.3 × 10−9). Targeted deletion of Pde3b in
mice leads to white adipose tissue gaining characteristics of
brown adipose tissue21, a reduction in adipocyte size22, smaller fat
deposits23 and reduced atherosclerosis24. We therefore studied
the association of PDE3B p.Arg783Ter with metabolic pheno-
types in UK Biobank and/or MIGen, where 36,581 individuals
have been sequenced for the 16 exons of the PDE3B gene. In UK
Biobank, which lacks direct measurements of blood lipids,
carriers of p.Arg783Ter carriers were at reduced risk of physician-
diagnosis of hypercholesterolemia (OR 0.52, P= 0.0002). Pooling
UK Biobank and MIGen, pLOF carriers in PDE3B had reduced
WHRadjBMI (beta −0.15, P= 0.0005). As genetic predisposition
to improved body fat distribution has been associated with a
lower risk of coronary artery disease25, we examined whether loss
of PDE3B function protects against coronary artery disease. We
aggregated rare PDE3B pLOFs in cases and compared this count
with that controls. Across 14,805 cases in UK Biobank, the carrier
frequency of pLOF in cases was 0.1% and in controls 0.2%. Across
20,186 cases in MIGen, the carrier frequency of pLOF was 0.05%
and 0.1% in controls. Collectively, carrier status for PDE3B
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Fig. 2 Association of IL33 c.487-1G > C with asthma in UK Biobank, Partners Biobank, Vanderbilt eMERGE network and Women’s Genome Health Study.
UK Biobank estimates were derived using logistic regression, adjusted for age, sex, ten principal components of ancestry, and array type. Partners Biobank
and Vanderbilt estimates were derived using logistic regression, adjusted for age, sex, and principal components of ancestry. Women’s Genome Health
Study estimates were derived using logistic regression, adjusted for age and principal components of ancestry
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Fig. 3 Association of predicted loss-of-function variant in GSDMB and IL33 with allergic disease in UK Biobank. Estimates were derived in UK Biobank using
logistic regression, adjusted for age, sex, ten principal components of ancestry, and array type
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pLOFs was associated with reduced risk for coronary artery
disease (OR 0.65 CI 0.43, 0.97; P= 0.03; Fig. 5).
Presence of homozygote individuals for pLOF variants in target
genes may provide an in vivo demonstration of safety of
pharmacologic inhibition of target genes. We therefore examined
whether homozygotes for these pLoF variants were present in UK
Biobank and in the gnomAD database26. At least one individual
homozygous for a pLOF variant was identiﬁed in UK Biobank or
the gnomAD database for the genes GPR151, GSDMB, IL33 and
IFIH1, and PDE3B (Supplementary Table 6).
Discussion
In this study, we identiﬁed pLOF variants that protect against
obesity (GPR151), asthma (GSDMB, IL33), autoimmune
disorders (IFIH1), and coronary artery disease (PDE3B),
prioritizing genes and pathways for which pharmacologic
attempts to mimic these protective mutations might ameliorate
disease.
Identiﬁcation of protective loss-of-function variants has led to
the development of therapeutics. Most notably, the discovery of
missense and loss-of-function variants in PCSK9 that lower LDL
cholesterol and protect against coronary artery disease suggested
that inhibition of PCSK9 may be a useful therapeutic strategy for
prevention and treatment of cardiovascular disease3,27. These
genetic studies were validated by a large-scale randomized trial
demonstrating that a monoclonal antibody directed against
PCSK9 reduced the risk of recurrent cardiovascular events4. More
recently, the discovery of loss-of-function variants in ANGPTL3
that lower blood triglyceride levels and protect against coronary
artery disease has suggested that ANGPTL3 inhibition may reduce
blood triglyceride levels and risk of coronary artery disease28,29.
ANGTPL3 inhibitors are in clinical development and have now
been demonstrated to reduce blood triglyceride levels5,6.
Our ﬁndings identify putative therapeutic targets that, similar to
PCSK9 and ANGPTL3, may be useful for prevention of disease.
For obesity and type 2 diabetes, these results hightlight GPR151 as
a potential therapeutic target. GPR151 encodes a largely
uncharacterized G protein-coupled receptor. The mechanism by
which it inﬂuences risk of obesity and type 2 diabetes is unclear.
However, it is highly expressed in the hypothalamus, a region of
the brain known to be involved in appetite regulation11. Indeed,
genetic variation in MC4R, which encodes the melanocortin 4
receptor, strongly inﬂuences obesity risk at a population level30.
Similar to GPR151, MC4Ris highly expressed in the hypothalamus
and is involved in appetite regulation31.
PDE3B inhibition may be a useful therapeutic strategy to
improve body fat distribution and reduce risk of coronary artery
disease. Unlike GPR151, for which no pharmacologic inhibitor is
currently in clinical use, an inhibitor of PDE3B is available.
Cilostazol is a non-selective pharmacologic inhibitor of both
phosphodiesterase 3B and the related isoform phosphodiesterase
3A32. In a small randomized trial including 211 participant,
cilostazol signiﬁcantly reduced restenosis after percutaneous
coronary balloon angioplasty33. The association of PDE3B pLOFs
with improved body fat distribution, reduced risk of hypercho-
lesterolemia and reduced risk of coronary artery disease suggests
that selective inhibition of PDE3B may be useful for multiple
features of metabolic syndrome.
We identiﬁed pLOF variants in IL33 (encoding interleukin 33)
and GSDMB (encoding gasdermin B) as associated with a lower
risk of asthma. The IL33 variant rs146597587 was recently found
to be associated with lower blood eosinophil concentration at
genome-wide signiﬁcance and with lower risk of asthma at more
modest levels of signiﬁcance (P= 1.8 × 10−4)15. Consistent with
these ﬁndings, induction of antibodies against IL33 by vaccina-
tion induces protection against airway inﬂammation in a mouse
model of asthma34. An inhibitor of IL33 is currently under
development for treatment of asthma16. In contrast to IL33,
no inhibitor for GSDMB is in clinical development. These
ﬁndings suggest that IL33 and GSDMB inhibition may both be
useful therapeutic strategies for treatment of asthma and allergic
disease.
Although our restriction of the present analysis to pLOF
variants increases the likelihood of identifying causal variants
substantially, it remains possible that a highly correlated nearby
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Fig. 4 Association of predicted loss-of-function variants in IFIH1 with thyroid disorders, type 1 diabetes, psoriasis, and vitiligo in UK Biobank. Estimates were
derived in UK Biobank using logistic regression, adjusted for age, sex, ten principal components of ancestry, and array type
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Fig. 5 Association of predicted loss-of-function variants in PDE3B with coronary artery disease. Estimates were derived in UK Biobank using logistic
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variant could be driving the association in some cases. Future
functional studies may permit additional validation of causal
variants.
In summary, we associated pLOF variants with a range of
biomarker and disease phenotypes in a large, national biobank
and identiﬁed several new genes in which pLOF variants protect
against disease, prioritizing these genes for therapeutic targeting.
More generally, large-scale analysis of pLOF variants is emerging
as a useful tool for therapeutic target identiﬁcation and validation.
Methods
Gene and variant annotation. Variants in hg19 coordinates were annotated with
information from Ensembl release 82 using Variant Effect Predictor (VEP)7. Only
pLOFs, deﬁned as premature stop (nonsense), canonical splice-sites (splice-donor
or splice-acceptor) or insertion/deletion variants that shifted frame (frameshift)
were annotated as predicted loss-of-function (pLOF), using the “--pick-allele”
annotation. PLOFs as deﬁned by VEP were then merged with publicly available
data from the Exome Aggregation Consortium (ExAC), Version 0.3.1, to conﬁrm
consistency in variant annotation26.
We identiﬁed 3759 pLOF variants in UK Biobank with an info score greater
than 0.3 (Supplementary Table 1). We used a Bonferroni corrected P value of 5.5 ×
10−7 to denote signiﬁcance [0.05/(3759 variants × 24 outcomes)= 5.5 × 10−7] in
our primary pLOF analysis.
Study design. We analyzed the association of pLOF variants with 24 phenotypes:
cardiovascular, metabolic and pulmonary phenotypes: six metabolic traits (body
mass index, waist-to-hip ratio, height, systolic blood pressure, diastolic blood
pressure, and forced expiratory volume to forced vital capacity ratio), six cardio-
metabolic diseases (coronary artery disease, type 2 diabetes, atrial ﬁbrillation,
stroke, heart failure, and venous thromboembolism) and 12 diseases with more
than 5000 cases (allergic rhinitis, asthma, anxiety, breast cancer, cataract, cho-
lethiasis, depression, hypothyroidism, gastric reﬂux, osteoporosis, osteoarthritis,
and psoriasis; Supplementary Table 4). All six metabolic traits were inverse nor-
malized prior to analysis, with adjustment for age and sex. Forced expiratory
volume to forced vital capacity ratio was additionally adjusted for height. To adjust
for the presence of antihypertensive medication, we added 15 mm Hg to systolic
blood pressure and 10 mm Hg to diastolic blood pressure of individuals on anti-
hypertensive medication at baseline, as in the International Consortium for Blood
Pressure genome-wide association study35. Deﬁnitions for disease outcomes in UK
Biobank are provided (Supplementary Table 7).
In UK Biobank, analysis was performed separately in unrelated individuals of
European and Non-European ancestry. Estimates for variants were then pooled
using inverse-variance weighted-ﬁxed effects meta-analysis. For coronary artery
disease, estimates for variants from UK Biobank were additionally pooled with the
effect of variants in the CARDIOGRAM Exome consortium using inverse variance
weighted-ﬁxed effects meta-analysis9. For height, estimates of variants in UK
Biobank were pooled with the GIANT Height Exome consortium using inverse
variance weighted-ﬁxed effects meta-analysis10.
Genotyping and quality control. Phasing and imputation were performed cen-
trally, by UK Biobank, using a reference panel combining UK10k and 1000 Gen-
omes samples. 39,235,157 variants included in the Haplotype Reference
Consortium were imputed. As recommended by UK Biobank, we excluded any
samples with an imputation quality <0.3 as well as pLOF variants which were not
included in the Haplotype Reference Consortium. Mitochondrial genetic data and
sex chromosomes were excluded from this analysis. Individual level genetic data
was available from individuals in UK Biobank, after excluding one related indi-
vidual of each related pair of individuals, individuals whose genetic sex did not
match self-reported sex and individuals with an excess of missing genotype calls or
more heterozygosity than expected.
We analysed 3759 variants identiﬁed as pLOF variants in UK Biobank. PLINK
2 software was used to examine the association of these variants with traits and
disease in UK Biobank under the assumption of additive effects (https://www.cog-
genomics.org/plink/2.0/). Adjustment was performed for age, sex, ten principal
components of ancestry, and array type.
Conditional analysis. A locus-wide conditional analysis (±500 kb of the pLOF
variant) was performed to determine the extent to which the identiﬁed pLOF
variant signal was independent of other genetic variation at the locus. We itera-
tively performed association analyses conditional on the top variants at each locus,
until no variants were below the Bonferroni-adjusted threshold for signiﬁcance (P
< 5.5 × 10−7). A statistically signiﬁcant and independent signal for the pLOF var-
iant provides increased conﬁdence for a causal association.
Analysis of PDE3B association with coronary artery disease. We aimed to
analyse the association of pLOF variants in PDE3B with coronary artery disease in
a combined analysis of UK Biobank and the Myocardial Infarction Genetics
Consortium (MIGen). Replication was performed in MIGen rather than the
CARDIOGRAM Exome consortium as rs150090666 was not included in the exome
chip analysis of the CARDIOGRAM Exome consortium9. Estimates of the asso-
ciation of rs150090666 with coronary artery disease in UK Biobank were derived as
described above, using logistic regression with adjustment for age, sex, ten principal
components of ancestry, and a dummy variable for array type. An additional pLOF
variant, rs535108921, present in UK Biobank, was also analysed for association
with coronary artery disease, as above.
pLOFs variants in PDE3B were identiﬁed in the MIGen Consortium using
exome sequencing or whole genome sequencing, as previously described36–38.
Studies included in the MIGen consortium were: (1) the Italian Atherosclerosis
Thrombosis and Vascular Biology (ATVB) study (dbGaP Study Accession
phs000814.v1.p1); (2) the Exome Sequencing Project Early-Onset Myocardial
Infarction (ESP-EOMI) study(9); (3) a nested case-control cohort from the Jackson
Heart Study (JHS); (4) the South German Myocardial Infarction study (dbGaP
Study Accession phs000916.v1.p1); (5) the Ottawa Heart Study (OHS) (dbGaP
Study Accession phs000806.v1.p1); (6) the Precocious Coronary Artery Disease
(PROCARDIS) study (dbGaP Study Accession phs000883.v1.p1); (7) the Pakistan
Risk of Myocardial Infarction Study (PROMIS) (dbGaP Study Accession
phs000917.v1.p1); (8) the Registre Gironi del COR (Gerona Heart Registry or
REGICOR) study (dbGaP Study Accession phs000902.v1.p1); (9) the Leicester
Myocardial Infarction study (dbGaP Study Accession phs001000.v1.p1); (10) the
BioImage study (dbGaP Study Accession phs001058.v1.p1); (11) the North
German Myocardial Infarction study (dbGaP Study Accession phs000990.v1.p1);
(12) Multi-Ethnic Study of Atherosclerosis (dbGaP Study Accession: phs000209.v2.
p1); (13) Variation In Recovery: Role of Gender on Outcomes of Young AMI
cohort; and (14) Taiwan Metabochip Consortium.
The Burrows–Wheeler Aligner algorithm was used to align reads from
participants to the reference genome (hg19). The GATK HaploTypeCaller
was used to jointly call variants. Metrics including Variant Quality Score
Recalibration (VQSR), quality over depth, and strand bias were then used
to ﬁlter variants. We excluded samples which were related to other samples,
which had high ratios of heterozygous to non-reference homozygous genotypes,
which had high missing genotypes, which had a discordant genetic gender
relative to reports gender, and samples which were discordant relative to
genotype data.
After variant calling and quality control, the Variant Effect Predictor7,8
was used to annotate variants which were pLOF: (1) nonsense mutations that
resulted in early termination of PDE3B (2) frameshift mutations due to insertions
or deletions of DNA; or (3) splice-site mutations which result in an incorrectly
spliced protein (Supplementary Table 8). For analysis of rare pLOF variants, we
pooled rare pLOF variants in MIGen, testing for the association of a pLOF with
coronary artery disease using logistic regression, after adjustment for age, sex,
cohort, and ﬁve principle components of ancestry. We meta-analysed the
association of pLOFs with coronary artery disease in MIGen combined with UK
Biobank.
Replication of IL33 ﬁnding. To replicate the association of rs146597587, a
splice site variant in IL33, with asthma, we pooled estimates of the association
of rs146597587 with asthma from Partners Biobank, from the Vanderbilt
eMERGE network and from the Women’s Genome Health Study. In Partners
Biobank, rs146597587 was imputed (info score of 0.77) in 2542 individuals.
The association of rs146597587 with asthma (hospitalization for ICD9 code 493)
was estimated using logistic regression, adjusted for age, sex, and ﬁve principal
components of ancestry. In the Vanderbilt eMERGE network, rs146597587
was genotyped in 25,363 individuals using the Illumina Exome BeadChip.
The association of rs146597587 with asthma (hospitalization for ICD9 code 493)
was estimated using logistic regression, adjusted for age, sex, and principal
components of ancestry. In Women’s Genome Health Study, rs14659758 was
genotyped in 22,618 individuals using the Illumina Exome. The association of
rs14659758 with asthma (hospitalization for ICD9 code 493 or ICD10 code J45)
was estimated using logistic regression, adjusted for age and principal components
of ancestry.
Data availability. All individual-level data from UK Biobank can be accessed by
applying to the UK Biobank Central Access Committee (http://www.ukbiobank.ac.
uk/register-apply/).
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